Expression of survivin in esophageal cancer: Correlation with the prognosis and response to chemotherapy

Kato, Jun; Kuwabara, Yoshiyuki; Mitani, Masami; Shinoda, Noriyuki; Satō, Atsushi; Toyama, Tatsuya; Mitsui, Akira; Nishiwaki, Takeshi; Moriyama, Satoru; Kudo, Junzo; Fujii, Yoshitaka

doi:10.1002/1097-0215(20010320)95:2<92::aid-ijc1016>3.0.co;2-9

Cited by 307 publications

(210 citation statements)

References 7 publications

Supporting

Mentioning

196

Contrasting

Order By: Relevance

“…Correspondingly, previous reports have shown that the presence of survivin is associated with poor survival among patients with colorectal cancer (Kawasaki et al, 1998), non small-cell lung cancer (Monzo et al, 1999), breast cancer (Tanaka et al, 2000) and neuroblastoma (Adida et al, 1998). In our study on 84 patients with oesophageal SCC, we now show that nuclear survivin protein is expressed in 80% of these tumours, thereby confirming and extending earlier results on mRNA expression of survivin in 51 oesophageal SCC patients (Kato et al, 2001). Furthermore, we could differentiate between cytoplasmic and nuclear localisation of survivin protein expression and were the first to show a translocation of survivin during carcinogenesis.…”

Section: Discussionsupporting

confidence: 90%

“…Expression of survivin protein is highly correlated with more aggressive forms of neuroblastoma (Adida et al, 1998) and oral and skin squamous cell carcinoma (Lo Muzio et al, 2001), and poor survival in patients with neuroblastoma (Adida et al, 1998), colorectal cancer (Kawasaki et al, 1998), nonsmall-cell lung cancer (Monzo et al, 1999), breast cancer (Tanaka et al, 2000) and increasing rates of recurrence in bladder cancer (Sherr and Roberts, 1995). By investigating mRNA expression of survivin, Kato et al (2001) found a significant correlation with a poorer prognosis and a worse response to chemotherapy in oesophageal cancer. Nevertheless, the expression and function of the survivin protein in oesophageal squamous cell carcinoma (SCC) is yet to be determined.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Prognostic value of nuclear survivin expression in oesophageal squamous cell carcinoma

et al. 2003

View full text Add to dashboard Cite

Survivin, a new member of the family of apoptosis inhibitors, is expressed almost exclusively in proliferating cells, above all in cancers. Subcellular localisation and prognostic implications of the survivin protein have not yet been determined in oesophageal squamous cell carcinoma. The survival of 84 patients with oesophageal squamous cell carcinomas was correlated with the extent of immunohistochemical survivin expression in tumour cell nuclei. Tumours were scored positive when 45% cells stained positive. Patients were followed up for at least 5 years or until death. In normal oesophageal squamous cell epithelium, some cytoplasmic survivin expression was detected in the basal cells, whereas proliferating cells showed nuclear staining of survivin. Nuclear expression of survivin was also detected in 67 cancers (80%). The mean survival for patients of this group (28 months, range 20 -36) was significantly less than that for patients without survivin expression in the tumour cell nuclei (108 months, range 62 -154, P ¼ 0.003). Using univariate analysis, nuclear survivin expression (P ¼ 0.003), tumour depth (P ¼ 0.001), lymph node metastasis (P ¼ 0.003) and stage (Po0.001) were the best predictors of survival. In contrast, cytoplasmic survivin staining was noted in 53 (63%) tumours and had no prognostic relevance. In conclusion, the analysis of nuclear survivin expression identifies subgroups in oesophageal squamous cell cancer with favourable (survivin À ) or with poor prognosis (survivin + ). We suggest that the determination of nuclear survivin expression could be used to individualise therapeutic strategies in oesophageal squamous cell cancer in the future.

show abstract

Section: Discussionsupporting

confidence: 90%

mentioning

confidence: 99%

Prognostic value of nuclear survivin expression in oesophageal squamous cell carcinoma

et al. 2003

View full text Add to dashboard Cite

show abstract

“…In this study, we demonstrated that survivin was not detected in the gastric mucosa from normal control subjects whereas the adjacent non-tumour gastric mucosa of survivin-positive tumours occasionally expressed survivin. This finding is in keeping with those found in colorectal and oesophageal cancer where survivin expression was demonstrated in adjacent normal tissues (Sarela et al, 2000;Kato et al, 2001). Past epidemiological studies revealed that first-degree relatives have an approximately three-fold increase in risk of developing gastric carcinoma, suggesting the existence of a genetic susceptibility to cancer (Zanghieri et al, 1990;La Vecchia et al, 1992).…”

Section: Discussionsupporting

confidence: 87%

Increased expression of survivin in gastric cancer patients and in first degree relatives

Leung

Ebert

et al. 2002

Br J Cancer

View full text Add to dashboard Cite

Survivin was recently described as an apoptosis inhibitor. Its pathogenic role in gastric cancer is largely unknown. Expression of survivin in gastric cancer and non-cancer first-degree relatives, and its association with apoptosis and cyclo-oxygenase-2 expression was investigated. Fifty gastric cancer, 30 non-cancer first-degree relatives, 20 normal controls and five gastric cancer cell lines were studied. Survivin and cyclo-oxygenase-2 were evaluated by reverse transcriptase-polymerase chain reaction, immunohistochemistry and Western blot. Survivin expression was absent from normal gastric mucosa. All five cancer cell lines and 34 out of 50 (68%) human gastric cancer tissues expressed survivin mRNA. Survivin expression was less frequent (22%; P50.001) in adjacent non-tumour gastric tissues. Immunohistochemistry and Western blot obtained similar findings. Gastric cancers with survivin expression displayed significantly reduced apoptosis (P=0.02), and associated with cyclo-oxygenase-2 overexpression at both mRNA (P=0.001) and protein levels (P=0.041). Moreover, survivin mRNA was detected in the gastric mucosa of eight (27%) non-cancer relatives. Expression in non-cancer patients showed positive correlation with H. pylori infection (P=0.004). This demonstrates the frequent expression of survivin in gastric cancer and in first-degree relatives. Coexpression of survivin and cyclo-oxygenase-2 may suggest multiple pathways contributing to the inhibition of apoptosis in gastric cancer.

show abstract

“…22 Survivin expression, nuclear in distribution by immunohistochemistry, and/or by RT-PCR is reported to be associated with unfavorable histology and aggressive disseminated disease in endometrial and ovarian carcinoma. 10,23 The overall survival in pulmonary non-small-cell carcinoma, 24 esophageal carcinoma, 25,26 gliomas, 27 soft-tissue sarcoma, 28 squamous laryngeal carcinoma, 29 and endometrial carcinoma 10 is significantly decreased in patients with neoplasms expressing survivin as compared to those with no expression. Disease-free survival is significantly decreased in patients with malignant melanoma, 30 and recurrence rate is increased in patients with neuroblastoma 31 when survivin is present in the neoplasm.…”

Section: Discussionmentioning

confidence: 99%

Survivin expression in hepatocellular carcinoma: correlation with proliferation, prognostic parameters, and outcome

et al. 2004

View full text Add to dashboard Cite

Survivin is a novel inhibitor of apoptosis. It is detected in fetal and neoplastic adult tissue, but not in normal tissues. Several recent studies have shown that survivin not only inhibits apoptosis, but also accelerates cancer cell proliferative activity. Expression of the protein may be of prognostic significance and therapeutic relevance in many cancers. We investigated survivin expression in hepatocellular carcinoma, correlating results with proliferation (MIB-1), prognostic factors, and outcome. Paraffin-embedded sections of 72 hepatocellular carcinoma were immunostained for survivin and MIB-1 using tissue microarray technology. Expression was evaluated in nuclei and cytoplasm as intensity (0-3 þ ), and percentage of positive cells scored on a four-tiered system with less than 10% ¼ negative; 10-25% ¼ 1; 26-50% ¼ 2; 51-75% ¼ 3; and 76-100% ¼ 4. Frequency of nuclear survivin expression was 43%. There was a significant correlation between nuclear survivin expression and nuclear grade (P ¼ 0.0271), microvascular invasion (P ¼ 0.0064), mitotic rate (P ¼ 0.0017), and MIB-1 (P ¼ 0.0001), as well as local recurrence (P ¼ 0.0487), and disease-free survival (P ¼ 0.0098). Histologic grade (P ¼ 0.0544) and stage (P ¼ 0.0548) tended to correlate with survivin expression, which did not correlate with cirrhosis, tumor necrosis, multiple tumors, metastatic disease, or overall survival. Survivin expression correlates with poor prognostic parameters (high nuclear and histologic grade, microvascular invasion, increased proliferation (mitotic count, MIB-1)), local recurrence, and shorter diseasefree survival, but does not correlate with overall survival. An important role is suggested for survivin in progression, recurrence, and treatment of hepatocellular carcinoma.

show abstract

Expression of survivin in esophageal cancer: Correlation with the prognosis and response to chemotherapy

Cited by 307 publications

References 7 publications

Prognostic value of nuclear survivin expression in oesophageal squamous cell carcinoma

Prognostic value of nuclear survivin expression in oesophageal squamous cell carcinoma

Increased expression of survivin in gastric cancer patients and in first degree relatives

Survivin expression in hepatocellular carcinoma: correlation with proliferation, prognostic parameters, and outcome

Contact Info

Product

Resources

About